Strategic Acquisition Intact Vascular is now part of Philips, expanding access to broader image-guided therapy platforms. Leverage Philips’ distribution channels and integrated sales approach to cross-sell Tack Endovascular System plus future peripheral vascular innovations to existing Philips customers.

Clinical Validation TOBA trial publications and early commercial use of the Tack Endovascular System demonstrate clinical credibility. Use this evidence in value propositions, case studies, and surgeon education programs to drive adoption among vascular specialists evaluating new peripheral interventions.

Growth Financing Recent equity-like financing and a significant debt facility indicate liquidity and growth potential. Position partnerships or rental/sponsorship options to banks, distributors, and hospital systems to accelerate deployments in mid-market vascular centers.

Global Expansion Philips acquisition aligns Intact Vascular with global reach. Target international hospitals and imaging-equipped centers in regions where Philips already has a presence, offering bundled solutions that combine imaging, guidance, and Tack Endovascular System.

Product Differentiation Minimal metal, 4F system and peripheral disease focus differentiate the portfolio. Create high-impact ROI messaging around reduced device profiles, potential procedural efficiency gains, and preserved future treatment options to appeal to SSO/vascular surgery decision-makers.